Products for Research Use Only
RegisterLogin

VIPhyb

CAT: 0804-HY-P5005-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P5005-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis[1][2][3][4].
CAS Number
125093-93-8
UNSPSC
12352209
Target
CMV; PD-1/PD-L1
Type
Peptides
Related Pathways
Anti-infection; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/viphyb.html
Purity
99.73
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC(C=C1)=CC=C1C[C@@H](C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@H](C(N)=O)CC(N)=O)=O)=O)=O)=O)=O)=O)CC2=CC=C(C=C2)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC3=CC=C(C=C3)O)=O)=O)=O)=O)NC([C@H]4N(CCC4)C([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H]5N(CCC5)C([C@@H](N)CCCCN)=O)=O)=O)=O)=O
Molecular Formula
C154H257N49O40S
Molecular Weight
3467.06
References & Citations
[1]Moody TW, et al. (Stearyl, Norleucine17) VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells. Life Sci. 1997;61 (17) :1657-66.|[2]Li JM, et al. VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice. PLoS One. 2013 May 27;8 (5) :e63381.|[3]Vu JP, et al. Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS) -induced colitis in mice. J Mol Neurosci. 2014 Jan;52 (1) :37-47.|[4]Emily R Summerbell, et al. Blocking VIP Signaling Abrogates Upregulation Of PD1 and Increases Proliferation Of Allo-Reactive T-Cells In a Mixed Lymphocyte Reaction, Blood, Volume 122, Issue 21, 2013, Page 1041.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported

Alternative Products

CatalogName
MBS5822520VIPhyb

Popular Products